Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
暂无分享,去创建一个
J. Bourhis | D. Blaise | J. Moatti | N. Milpied | J. Jouet | P. Bordigoni | M. Attal | L. Sutton | M. Kuentz | J. Cahn | J. Jouet | M. Michallet | J. Moatti | J. Boiron | C. Fortanier | M. Schuller | Jean-Yves Cahn | Marie-Pascale Schuller | J. Cahn | M. Schuller
[1] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[2] F. Aversa,et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor , 1999, The Lancet.
[3] J. Blache,et al. OPTIMIZATION OF PERIPHERAL BLOOD STEM CELL COLLECTION BY LEUKOPHERESIS , 1999, International Journal of Technology Assessment in Health Care.
[4] M. Beksac,et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] D. Blaise,et al. Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study , 1998, Bone Marrow Transplantation.
[6] N. Schmitz,et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.
[7] K. Sullivan,et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. , 1997, Blood.
[8] N. Schmitz,et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model : Evidence for an improved graft-versus-leukemia effect , 1997 .
[9] N. Schmitz,et al. Allogeneic blood stem cell transplantation: considerations for donors. , 1997, Blood.
[10] D. Blaise,et al. Early establishment of chimerism in the B and T lymphoid lineages after transplantation of allogeneic mobilized blood cells in leukemic patients. , 1997, Transplantation.
[11] D. Blaise,et al. Early and fatal immune haemolysis after so-called ‘minor’ ABO-incompatible peripheral blood stem cell allotransplantation , 1997, Bone Marrow Transplantation.
[12] D. Blaise,et al. Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial , 1997, Annals of Internal Medicine.
[13] A. Gratwohl,et al. Blood and marrow transplantation activity in Europe 1995 , 1997, Bone Marrow Transplantation.
[14] J. Garcia-conde,et al. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT. , 1997, Haematologica.
[15] R. Storb,et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. , 1996, Blood.
[16] D. Feeny,et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Santoro,et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. , 1996, Bone marrow transplantation.
[18] N. Schmitz,et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.
[19] J. Ferrara,et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.
[20] R. Storb,et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Storb,et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor , 1995 .
[22] A. Deisseroth,et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts , 1995 .
[23] N. Schmitz,et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.
[24] D. Blaise,et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. , 1994, Bone Marrow Transplantation.
[25] M. Pepe,et al. Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methods , 1993, British journal of haematology.
[26] S. Goodman,et al. Factors influencing third party payer costs for allogeneic BMT. , 1993, Bone marrow transplantation.
[27] J. Reiffers,et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. , 1992, Bone marrow transplantation.
[28] J. Bergerat,et al. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients. , 1991, Bone marrow transplantation.
[29] D. Jolly,et al. Cost of allogeneic bone marrow transplantation in four diseases. , 1989, Health policy.
[30] J. Doroshow,et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789] , 1987 .
[31] H. Deeg,et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.
[32] J R Anderson,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Eisenberg. New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations. , 1984, Reviews of infectious diseases.
[34] Jean E. Sanders,et al. Marrow harvesting from normal donors. , 1984, Blood.
[35] R. Brookmeyer,et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.
[36] S. Finkler. The distinction between cost and charges. , 1982, Annals of internal medicine.
[37] K. Sullivan,et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.
[38] R. Powles,et al. COST OF BONE-MARROW TRANSPLANTS IN ACUTE MYELOID LEUKÆMIA , 1980, The Lancet.
[39] R Storb,et al. Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.
[40] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.
[41] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.